Levamisole serves as an anthelmintic agent used for parasite management. Parasitic neuromuscular systems are modulated to trigger paralysis, allowing for the natural expulsion of organisms from the host's intestinal tract.
Targeting intestinal parasites, Levamisole belongs to the imidazothiazole class of anti-helminthic agents. Chemically, it is a small heterocyclic molecule that interferes with the neuromuscular function of certain worms, leading to paralysis and expulsion. In humans, the substance also displays modest immunomodulatory activity, which has prompted its inclusion in several therapeutic regimens. It is the active compound found in formulations such as Dicaris, marketed for specific parasitic infections.
Beyond its role against hookworms and roundworms, the agent has been explored for adjunctive use in oncology and inflammatory disorders due to its ability to stimulate certain immune cells. Regulatory approval in Singapore limits its availability to prescription-only products, reflecting a balance between efficacy and safety considerations. The chemical’s stability and oral absorption make it suitable for tablet forms, the most common delivery method for patients.
Formulated for convenient oral intake, Levamisole appears primarily as film-coated tablets ranging from 150 mg to 300 mg strengths. Dicaris, a branded product in Singapore, follows this tablet format and is supplied by a locally authorized distributor. Generic versions share the same active dose but may differ in excipients, coloring agents, and manufacturer imprint.
In the Singaporean market, both branded and generic tablets are subject to Health Sciences Authority (HSA) review, ensuring comparable quality and bioavailability. While the active ingredient remains identical, variations in tablet size or coating can affect patient preference. The medication is typically packaged in blister packs to protect against moisture and physical damage.
Addressing hookworm and roundworm infections, the agent reduces parasite burden and alleviates related gastrointestinal discomfort. It is also employed in selected cases of pediatric ascariasis where alternative treatments are unsuitable. In oncology, Levamisole has been used as an adjuvant to standard chemotherapy for colorectal cancer, aiming to enhance immune surveillance. Additionally, clinical trials have examined its modest benefit in certain inflammatory skin conditions, such as chronic urticaria, where immune modulation may alleviate symptoms.
Patients receiving the drug are generally those diagnosed with confirmed helminthic infection or enrolled in controlled oncology protocols. The medication is selected when its dual anti-parasitic and immunostimulatory profile aligns with therapeutic goals, often after evaluating other available agents.
Interrupting the parasite’s nerve signals, the substance blocks acetylcholine receptors on the worm’s muscle cells, causing loss of coordination and eventual death. In the human immune system, it promotes the activity of T-lymphocytes and natural killer cells, offering a supportive boost during cancer treatment. These actions occur without substantial alteration of the patient’s own nerve function, making the side-effect profile largely related to gastrointestinal and immune responses.
Mild nausea, abdominal cramps, and transient skin rashes occur in some individuals shortly after ingestion. These effects typically resolve without medical intervention.
Rare cases of severe neutropenia, agranulocytosis, or hypersensitivity reactions have been reported, presenting as fever, sore throat, or difficulty breathing. Prompt medical evaluation is advised if such symptoms develop.
Pregnant or breastfeeding persons should avoid the medication due to potential fetal risks. Individuals with known hypersensitivity to imidazothiazoles or with compromised immune systems require careful assessment before use.
Concurrent use of alcohol or drugs that suppress bone marrow function may amplify adverse effects. Patients should refer to the specific medication’s insert for a complete interaction list, as formulations can differ in excipient content.
Storing the tablets in a cool, dry place protects their potency throughout the prescribed course. Treatment courses for parasitic infections typically span a few days, whereas oncologic protocols may involve repeated cycles over months. Variability in dosage strength between Dicaris and other products underscores the importance of following the label instructions.
For detailed usage, dosing, and administration, refer to the specific medication's clinical information.
This educational overview of Levamisole is not medical advice; individual medicines such as Dicaris differ in strength, formulation, and instructions. The provider disclaims liability for any clinical application of the information herein. Patients should consult their specific medication labeling and a licensed healthcare professional for personalized guidance.
